Pro-Dex Inc

Pro-Dex Inc(PDEX)股票分析

$63.440

+3.369 (+5.31%)收盤時

Loading chart…
最高
63.660
開盤
61.010
成交量加權均價
62.70
成交量
38.94K
市值
64.62M
最低
61.010
成交金額
2.44M
企業價值/稅息折舊攤銷前利潤(TTM)
12.25

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. The Company has patented adoptive torque-limiting software and sealing solutions, which appeal to its customers, primarily medical device distributors. It also manufactures and sells rotary air motors to a range of industries. The Company’s medical device products utilize designs developed by it primarily under development and supply agreements and are machined in its Irvine, California facility, and assembled in its Tustin, California facility, as are its rotary air motors. Its medical device products are sold primarily to original equipment manufacturers and its air motors are sold primarily to a range of distributors and end users. It manufactures machined sub-assemblies and also produces parts and assemblies for aerospace and defense systems.

AI 分析 of Pro-Dex Inc (PDEX)

持有

Currently, Pro-Dex Inc (PDEX) is trading at $57.65, which is significantly below its 52-week high of $77.00, indicating potential for recovery. However, the RSI is at 29.815, suggesting it is in oversold territory, which could lead to a rebound. The forward P/E ratio is 19.12, indicating that the stock may be overvalued based on future earnings expectations. The company reported a net income of $13.66 million for FY 2026, a 52% increase from the previous year, which is a positive sign for long-term investors. However, the stock has seen a 4.96% decline over the past five days, which reflects short-term volatility. Given these factors, it may be prudent to hold rather than buy at this moment, as the stock could stabilize before making a more informed investment decision.

分析師評級(1)

買進
1 買進
0 持有
0 賣出
目前: 63.44
最低
—
平均
—
最高
—

Ascendiant Capital

2024-11-11

目標價

$52

強烈買進

Ascendiant Capital

2024-09-09

目標價

$30

強烈買進

估值指標

Pro-Dex Inc(PDEX)目前預期本益比為 18.66,5 年平均預期本益比為 17.42。

預期本益比

合理
5 年均值 P/E
17.42
目前P/E
18.66
高估
23.31
低估
11.53

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
10.48
目前EV/EBITDA
12.25
高估
13.50
低估
7.45

預期股價營收比

高估
5 年均值 P/S
1.70
目前P/S
2.22
高估
2.19
低估
1.20

Alphio AI 對 PDEX 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%PDEX

$55.23

情境價格

基

基準

基準 · 50%PDEX

$51.89

情境價格

悲

悲觀

悲觀 · 25%PDEX

$51.20

情境價格

PDEX 常見問題 —— 由 Alphio AI 解答

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. The Company has patented adoptive torque-limiting software and sealing solutions, which appeal to its customers, primarily medical device distributors. It also manufactures and sells rotary air motors to a range of industries. The Company’s medical device products utilize designs developed by it primarily under development and supply agreements and are machined in its Irvine, California facility, and assembled in its Tustin, California facility, as are its rotary air motors. Its medical device products are sold primarily to original equipment manufacturers and its air motors are sold primarily to a range of distributors and end users. It manufactures machined sub-assemblies and also produces parts and assemblies for aerospace and defense systems. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Currently, Pro-Dex Inc (PDEX) is trading at $57.65, which is significantly below its 52-week high of $77.00, indicating potential for recovery. However, the RSI is at 29.815, suggesting it is in oversold territory, which could lead to a rebound. The forward P/E ratio is 19.12, indicating that the stock may be overvalued based on future earnings expectations. The company reported a net income of $13.66 million for FY 2026, a 52% increase from the previous year, which is a positive sign for long-term investors. However, the stock has seen a 4.96% decline over the past five days, which reflects short-term volatility. Given these factors, it may be prudent to hold rather than buy at this moment, as the stock could stabilize before making a more informed investment decision.

1 analysts cover PDEX: 1 rate it Buy, 0 Hold and 0 Sell.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易